February 21, 2024 12:00 PM EST
Financing
Bioregnum

The top 100 ven­ture play­ers in bio­phar­ma to­day. Who's in? What's out?

2023 marks one of those years in life sci­ences when ven­ture cap­i­tal spent a lot of time look­ing for ways to pre­serve cash run­ways and …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times